Yuhan Corporation Receives Second Milestone from Janssen for Lazertinib

[Asia Economy Reporter Cho Hyun-ui] Yuhan Corporation announced on the 23rd that it will receive the second milestone payment of $65 million (approximately 72.3 billion KRW) for the lung cancer drug 'Lazertinib,' which was licensed out to the multinational pharmaceutical company Janssen.

Lazertinib is a targeted therapy being developed for first-line treatment of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations or second-line treatment of NSCLC patients with the EGFR T790M mutation.

This milestone payment follows the initiation of Phase 3 clinical trials for the combination therapy of Lazertinib and Janssen's 'Amivantamab.'

Yuhan Corporation licensed Lazertinib, a treatment for non-small cell lung cancer, to Janssen in November 2018 and has been co-developing the drug since then. The total contract value at that time was 1.4 trillion KRW.

Yuhan Corporation is also continuing the development of Lazertinib as a monotherapy for non-small cell lung cancer patients. Currently, a multinational Phase 3 clinical trial is underway to confirm its efficacy and safety as a first-line treatment.